← All trials
NCT06753890
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2024
- Primary completion
- Nov 11, 2026
- Completion date
- Dec 30, 2026
- First posted
- Dec 31, 2024
- Last posted
- Dec 31, 2024
- Enrollment
- 520
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tasly Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.